SCHEMBL708913

SCHEMBL708913

Cc1cnccc1B(O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT3 Q9NTG7 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TRPA1 O75762 1/20 0.37
CCNC P24863 2/20 0.34
CDK8 P49336 2/20 0.34
CYP2A6 P11509 3/20 0.33
CYP2E1 P05181 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2B6 P20813 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C8 P10632 1/20 0.32
CA2 P00918 1/20 0.32
LPL P06858 1/20 0.32
LIPG Q9Y5X9 1/20 0.32
GRM4 Q14833 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
ALOX5 P09917 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL14797240 0.98 SIRT3 (0.39) SIRT3TDP1TRPA1CCNCCDK8
Hydrochloric Acid SCHEMBL29958203 0.98 SIRT3 (0.39) SIRT3TDP1TRPA1CCNCCDK8
SCHEMBL248787 0.81 SIRT3 (0.45) SIRT3TDP1TRPA1CYP2A6CYP2E1
SCHEMBL29628428 0.81 SIRT3 (0.45) SIRT3TDP1TRPA1CYP2A6CYP2E1
Hydrochloric Acid SCHEMBL29954682 0.79 SIRT3 (0.44) SIRT3TDP1TRPA1CYP2A6CYP2E1
Hydrochloric Acid SCHEMBL15953194 0.79 SIRT3 (0.44) SIRT3TDP1TRPA1CYP2A6CYP2E1
Hydrochloric Acid SCHEMBL14811865 0.79 NPC1 (0.38) SIRT3TDP1CYP3A4CA2LPL
SCHEMBL29952734 0.76 KDM4E (0.38) SIRT3TDP1
SCHEMBL22489854 0.76 KDM4E (0.38) SIRT3TDP1
SCHEMBL1896645 0.74 ALDH1A1 (0.45) SIRT3TDP1CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 474 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637467-B2 Inhibitor of BTK and mutants thereof NEWAVE PHARMACEUTICAL INC. (US) 2026-05-26 US disclosed
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 CN disclosed
CN-122010905-A Pyrazolyl derivatives as anticancer agents 诺华股份有限公司 2026-05-12 CN disclosed
EP-4737448-A1 SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF Artivila (ShenZhen) Innovation Center, Ltd. (CN) 2026-05-06 EP disclosed
EP-4344702-B1 PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS NOVARTIS AG (CH) 2026-01-28 EP disclosed
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2025-10-09 US disclosed
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
US-20250289792-A1 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 SOLENT THERAPEUTICS LLC (US) 2025-09-18 US disclosed
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-08-05 US disclosed
US-20250230168-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. 2025-07-17 US disclosed
WO-2008130320-A2 NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
US-20080269249-A2 AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS ALCON, INC. (CH) 2008-10-30 US disclosed
US-20080139583-A1 PHOSPHODIESTERASE 4 INHIBITORS TEHIM ASHOK 2008-06-12 US disclosed
US-7332486-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2008-02-19 US disclosed
EP-1830853-A2 AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES ALCON INC. (CH) 2007-09-12 EP disclosed
US-20070093510-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-26 US disclosed
WO-2006071548-A2 AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES ALCON, INC. (CH) 2006-07-06 WO disclosed
US-20060142307-A1 Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions ALCON, INC. 2006-06-29 US disclosed
EP-1529049-A2 DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2005-05-11 EP disclosed
WO-2004014913-A2 DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230168-A1 AZASPIRO WRN INHIBITORS WRN, RECQL, BLM SIRT3 1157/4885TDP1 54/4885TRPA1 4790/4885
US-20070093510-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE3B, PDE3A SIRT3 568/4885TDP1 70/4885TRPA1 3425/4885
US-20080139583-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE3A SIRT3 568/4885TDP1 70/4885TRPA1 3425/4885
US-20250289792-A1 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 TPX2, CBX2, RIOX2 SIRT3 4617/4885TDP1 1765/4885TRPA1 3070/4885
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor IRAK4, IRAK1, IRAK2 SIRT3 1412/4885TDP1 568/4885TRPA1 1357/4885
US-20080269249-A2 AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS ROCK2, ROCK1, RHOA SIRT3 2964/4885TDP1 1243/4885TRPA1 4111/4885
US-12637467-B2 Inhibitor of BTK and mutants thereof BTK, CNKSR1, SYK SIRT3 3701/4885TDP1 1478/4885TRPA1 2605/4885
US-20060142307-A1 Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions ROCK2, ROCK1, RHOA SIRT3 2964/4885TDP1 1243/4885TRPA1 4111/4885
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS ADORA2A, ADORA2B, ADORA1 SIRT3 3132/4885TDP1 687/4885TRPA1 297/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 SIRT3 750/4885TDP1 1125/4885TRPA1 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.